Cargando…

More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes

On 9 December2019, the Institute for Clinical and Economic Review (ICER) released its final evidence report to establish the value of oral semaglutide (Novo Nordisk) for Type 2 diabetes (T2DM). A key element in this report was the development of a lifetime cost effectiveness microsimulation model ba...

Descripción completa

Detalles Bibliográficos
Autor principal:	Langley, Paul C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	University of Minnesota Libraries Publishing 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132533/ https://www.ncbi.nlm.nih.gov/pubmed/34017637 http://dx.doi.org/10.24926/iip.v11i1.2420

Ejemplares similares

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

ICER, ISPOR AND QALYs: Tales of Imaginary Worlds
por: Langley, Paul C
Publicado: (2019)

CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018)

Nonsense on Stilts – Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds
por: Langley, Paul C
Publicado: (2020)

More Unnecessary Imaginary Worlds – Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review’s Draft Evidence Report
por: Langley, Paul C
Publicado: (2020)

Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
por: Langley, Paul C
Publicado: (2019)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
por: Langley, Paul C
Publicado: (2020)

Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies
por: Langley, Paul C
Publicado: (2019)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement
por: Langley, Paul C
Publicado: (2020)

The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment
por: Langley, Paul C
Publicado: (2020)

The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies
por: Langley, Paul C
Publicado: (2019)

Evidence for tuning adipocytes ICER levels for obesity care
por: Brajkovic, Saška, et al.
Publicado: (2012)

Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience
por: Langley, Paul C
Publicado: (2021)

Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review
por: Langley, Paul C
Publicado: (2021)

Oral Semaglutide: Dosage in Special Situations
por: Kalra, Sanjay, et al.
Publicado: (2022)

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms
por: Langley, Paul C
Publicado: (2023)

Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims
por: Langley, Paul C
Publicado: (2021)

The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2020)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

The use of real-world evidence in ICER’s scoping process and clinical evidence assessments
por: Jiao, Boshen, et al.
Publicado: (2020)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson, Sam, et al.
Publicado: (2019)

Building Imaginary Worlds
por: Wolf, Mark
Publicado: (2014)

Semaglutide for type 2 diabetes
Publicado: (2020)

CERN: Real and imaginary parts
Publicado: (1993)

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
por: Evans, Marc, et al.
Publicado: (2022)

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
por: Kane, Michael P, et al.
Publicado: (2020)

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
por: Candido, Riccardo, et al.
Publicado: (2023)

The evolution of ICER’s review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER’s reports
por: Ronquest, Naoko A, et al.
Publicado: (2021)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
por: Selvarajan, Raja, et al.
Publicado: (2023)

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
por: Breslau, Rachel Milstein, et al.
Publicado: (2022)

Imaginary Worlds and Their Borders: An Opinion Article
por: Wiepke, Axel, et al.
Publicado: (2021)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
por: Liu, Yalin, et al.
Publicado: (2022)

Commentary: Don't stress for the unnecessary stress
por: Alsoufi, Bahaaldin
Publicado: (2020)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
por: Guzauskas, Gregory F, et al.
Publicado: (2021)

ICER is requisite for Th17 differentiation
por: Yoshida, Nobuya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nkfis2itl4v01gvjh7td6v4pad